Alavita Pharmaceuticals is a privately held biotechnology company to discover and develop treatments for ischemia/reperfusion injury (IRI). IRI impacts tissues and organs that have been temporarily deprived of blood flow and thus inhibitors would be expected to improve function of transplanted organs.